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Abstract
Alzheimer’s disease (AD) is one of the most common causes of dementia. Despite several decades 
of serious research in AD there is no standard disease modifying therapy available. Stem cells hold 
immense potential to regenerate tissue systems and are studied in a number of brain-related 
disorders. For various untreatable neurodegenerative disorders, such as Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) (current-approved drugs provide 
only symptomatic relief), stem cell therapy holds a great promise and provides a great research 
opportunity. Here we review several stem cell transplantation studies with reference to both 
preclinical and clinical approaches. We focus on different sources of stem cells in a number of 
animal models and on molecular mechanisms involved in possible treatment of neurodegenerative 
disorders. The clinical studies reviewed suggest safety efficacy and translational potential of stem 
cell therapy. The therapeutic outcome of stem cell transplantation has been promising in many 
studies but no unifying hypothesis exists for an underlying mechanism. Some studies reported 
paracrine effects exerted by these cells via release of neurotrophic factors, while other studies 
reported immunomodulatory effects by transplanted cells. There are also reports supporting stem 
cell transplantation causing endogenous cell proliferation or replacement of diseased cells at the 
site of degeneration. In animal models of AD, stem cell transplantation is also believed to increase 
expression of synaptic proteins. A number of stem cell transplantation studies point out great 
potential for this novel approach in preventing or halting several neurodegenerative diseases. The 
current challenge is to clearly define the molecular mechanism by which stem cells operate and 
the extent of actual contribution by the exogenous and/or endogenous cells in the rescue of 
disease.
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INTRODUCTION: THE POTENTIAL OF STEM CELL TRANSPLANTATION IN 
ALZHEIMER’S DISEASE
A number of neurodegenerative disorders, such as Alzheimer’s disease (AD), Amyotrophic 
lateral sclerosis (ALS) and Parkinson’s disease (PD) are untreatable, and they progressively 
worsen with age, resulting in death. The world Alzheimer Repot 2015 reported over 46 
million individuals in the world’s population suffer from dementia, and this number is 
estimated to increase upto 131.5 million by 2050 [1]. Dementia is associated with multiple 
causes that include alcoholism, AD, stroke, PD and drug/medication intoxication. It is the 
fifth leading cause of death in the US with age of 65 years or above. In 2015 AD prevalence 
in USA was estimated to be close to 5.3 million, and this is expected to rise up to 11 to 16 
million in 2050 [2]. In India, the number of individuals which are suffering from AD and 
other dementia is estimated to be approximate 3.7 million and this number is expected to 
double by the year 2030 [3].
The most common form of dementia, AD, is characterized by different stages of cognitive 
and functional impairment. Patients suffering from AD lose autonomy in their daily normal 
activities, and this progressively deteriorates with age. In 1901, Alois Alzheimer, a German 
psychiatrist, diagnosed a 51 year-old woman with a condition he called “amnestic writing 
disorder” [4]. Her psychosocial abnormalities included aphasia and memory impairment. 
Later, in 1910 when Alzheimer’s supervisor published his book Psychiatrie, he reported this 
case and mentioned this condition as Alzheimer’s disease [4]. Since then, extensive research 
has progressed worldwide to understand several aspects of the disease, ranging from its 
pathology, disease onset, prevalence, diagnosis and treatment in various cellular, pre-clinical 
and clinical studies. Currently, AD pathophysiology is based on several important 
hypotheses i.e., including the cholinergic hypothesis, protein misfolding, and amyloid 
cascade hypotheses [5–7].
The hippocampus plays a significant role in memory encoding and retrieval. Hippocampus is 
the first region of the brain to be affected in AD. Injury to brain tissue has not been seriously 
considered for treatment by cell replacement strategies as compared to the other organs e.g. 
skin and liver tissues. Earlier, neuroanatomists considered that the nervous system is 
incapable of regeneration. In 1962 Joseph Altman provided the first evidence of 
neurogenesis in the cerebral cortex and later, in 1963 he showed the occurrence of 
neurogenesis in the dentate gyrus of rat and cat hippocampus [8]. In some animals, neuronal 
precursors originate from the subventricular zone (SVZ) to the main olfactory bulb via 
specialized migratory route known as the rostral migratory stream (RMS). More recently, 
various strategies are being employed to activate these lesser population of stem cells by 
various methods [9]. Currently available FDA-approved drugs for AD provide symptomatic 
relief to the patients without alleviating elusive disease pathology. Alternative strategies such 
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as herbal remedies [10–12] and cell based therapies [13, 14] are being tested in preclinical 
settings with the hope of halting disease progression. The underlying mechanism is either 
replacement of degenerating neurons or exerting neuroprotection by the paracrine effect of 
transplanted cells by the secretion of neurotrophic factors (Fig. 1) [15]. The efficacy of stem 
cells has been studied in various pre-clinical studies by transplanting these cells into the 
disease- specific animal models. However, there is a gap of knowledge describing the 
underlying molecular mechanisms involved in the rescue of disease by transplanted cells.
PATHOPHYSIOLOGICAL FEATURES IN ALZHEIMER’S DISEASE
Several animal studies and human brain biopsies have revealed the pathological hallmarks of 
AD, including extracellular amyloid-β (Aβ) plaque deposits and formation of intracellular 
neurofibrillary tangles (NFT). NFT are misfolded structures produced by aberrant 
phosphorylation of microtubule-stabilizing tau proteins. The process of Aβ formation is 
known to play a significant role in AD etiology [16]. Amyloid plaques may trigger a 
pathological cascade resulting in neurofibrillary tangles and neuroinflammation causing 
neuritic dysfunction, which ultimately leads to neuronal death. In AD patients, excessive 
accumulation of amyloid plaques is likely to be due to dysregulation of activity of β-site 
Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1). BACE1 gives rise to Aβ from the 
membrane-spanning Aβ precursor protein (APP). This is the rate limiting step of Aβ 
production. This cleavage occurs at the N-terminus of Aβ to form soluble APPβ, and the C-
terminus is further cleaved by γ-secretase complex, which yields Aβ40/42 [17]. Aβ 
fragments thus generated aggregate to form amyloid fibrils. Aβ40 (with 40 amino acid 
residue) is the predominant form but Aβ42 (with 42 residues) is more fibrillogenic than the 
shorter species and is involved in disease pathology.
Several environmental factors cause epigenetic changes in individuals. It plays a significant 
role in regulating the gene expression via modification of DNA and histone protein 
modification leading to genetic dysregulation thereby causing various disease pathologies. In 
AD, amyloid fibril-induced neuroinflammation is believed to increase expression of 
epigenetic factors such as. methyl-CpG-binding protein 2 and histone deacetylase 2 and their 
interaction further suppresses the expression of synaptic protein leading to amyloid induced 
memory deficiency [18].
Tau is an intracellular microtubule associated protein that plays an essential role in 
microtubule stabilization. Abnormal phosphorylation of tau leads to microtubule disruption. 
The formation of neurofibrillary tangles may be triggered by amyloid plaque. In addition, 
the cholinergic hypothesis postulates a reduction in neurotransmitter acetylcholine in the AD 
patients [19] as the primary cause of AD. Besides amyloid plaque deposition and 
neurofibrillary tangle formation, vascular dysfunction also appears in AD pathophysiology.
Both genetic and environmental factors contribute to etiology of AD. Genetic factors linked 
to autosomal dominant inherited mutations include presenilin 1 (PS1), presenilin 2 (PS2), 
APP and enzymes involved in amyloid processing, such as BACE1. This genetic form, also 
called familial AD (FAD) contributes marginally towards prevalence (no more than 5% of 
AD cases [20]), whereas most AD cases are sporadic, with an unknown cause. The E4 
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variant of APOE is largely known as a major genetic risk factor for the late onset of AD 
[21]. Studies suggest that there are some interactions with amyloid to cause this dramatic 
effect [22]. Some studies also propose that sporadic cases are the result of various 
environmental and epigenetic factors which lead to an etiology based upon “Latent Early-
life Associated Regulation” (LEARn). LEARn describes effects resulting from exposure of 
stressors in early life e.g. nutritional imbalance, toxic metals (such as lead) and other 
stressors, which induce epigenetic alterations on disease associated gene chromatin or 
histones [23]. These changes remain latent as (de)methylation of promoter or chromatin 
modifications by (de)acetylation, (de)methylation and (de)phosphorylation. Upon one or 
more additional hits in the later life, expression of modified gene(s) alters sufficiently to 
induce pathology.
CELL TYPE CONSIDERATIONS FOR DISEASE MODIFYING THERAPIES
The requirement of a suitable cell type with particular characteristics for specific disease 
types is needed for proper and effective cell transplantation. Stem cells from several tissues 
such as bone marrow and umbilical cord blood are well characterized for their proliferation 
and differentiation properties and can be an optimum source for transplantation [24, 25]. 
Current strategies emphasize culturing of isolated cells in an optimum medium with suitable 
nutrient environment to obtain the desired disease phenotype. The microenvironment also 
provides suitable niche for selective expression of desirable markers to trigger these cells for 
a specialized cell type [26, 27]. Long-term culture and characterization of primary neurons 
isolated from rodent and human fetal tissue is essential for undertaking comparative studies. 
Abundant tau and amyloid-β production in human brain cultures provides a powerful 
cellular model for AD. In a recent study Ray et al provide a well-characterized methodology 
for fetal human primary brain cell culture, which is useful to test the therapeutic efficacy of 
drugs targeting AD [28]. Cultures of induced pluripotent stem cell (iPSC) generated from 
fibroblasts of FAD patients with presenilin 1 and presenilin 2 mutations were characterized 
after acquiring neuronal lineage [29]. Apart from increased Aβ42 expression, the iPSC 
model also showed variable drug response and alleviation of stress induced response by 
docosahexaenoic acid (DHA) treatment [30]. Likewise, RNA silencing has also been used in 
this cellular model. Therapeutic strategies primarily focus on targeting production of Aβ by 
identifying key molecular regulators of BACE1 expression. The researchers have also 
elucidated the role of human micro-RNA (miR)-339-5p which negatively modulates BACE1 
in primary human brain cultures, and expression of miR-339-5p is reduced in AD patients 
[31].
PRE-CLINICAL STUDIES TO PROBE REGENERATIVE POTENTIAL OF STEM 
CELLS
At present, there are no consensus measures to accurately diagnose and monitor progression 
of AD [32]. This significantly hinders effective treatments against AD. To study AD 
pathologies and its targets, different animal models of AD have been established and tested 
in preclinical settings. These model systems range from laboratory animals like zebrafish, 
murid rodents and nonhuman primates to model invertebrates such as Drosophila and C 
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elegans. Among these, rats and mice are widely used, and their transgenic counterparts are 
the most-established system to evaluate disease pathophysiology as well as effective 
treatment strategies. Several strategies have been adopted to establish AD like pathologies 
and induced memory impairment in these models [33]. These include predetermined brain 
injury, neurotoxin induced cell loss in brain and intra-cerebroventricular injection of Aβ 
peptides [34].
Current treatments for AD includes blocking neurotransmitter degradation, which provide 
temporary symptomatic relief without alleviating the pathophysiological burden of the 
disease [35, 36]. Therefore, alternative cell based studies for transplantation have been 
carried out in the belief that either these cells replace degenerating neurons or secrete trophic 
factors that provide a protective environment to the endogenous cells. Various neurotrophic 
factors are secreted by the cells to modulate the synaptic functioning in brain. In particular, 
BDNF is synthesized by neurons and highly expressed in cortex and hippocampus; these 
regions are crucial for learning and memory in brain [37].
The animal models associated with Aβ-induced memory loss have been widely studied in 
understanding pathophysiology of AD and testing therapeutic efficacy of various drug 
targets. Prakash et al. use intracerebroventricular (ICV) injection of Aβ to study the role of 
pioglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, on 
neurotrophic factor BDNF in a rat model of AD with neuroinflammation. Aβ-injured 
animals showed significant impairment in memory as well as reduced levels of BDNF, 
which were reversed by administration of pioglitazone [38]. Tang et al. demonstrated 
fibrillar Aβ40 induced neurotoxicity in rat hippocampus, characterized by congo red plaques 
and degenerating neurons at the site of injection. This pathological outcome was supported 
by impaired cognitive performance in the rats, tested in Morris water maze. Further, they 
have used this model to validate cell replacement efficacy of neural precursor cells derived 
from human embryonic stem cells. The neural precursor cells are partially differentiated, as 
these cells are more precisely committed to their lineage [39]. The transplanted cells were 
found to ameliorate Aβ-induced cognitive impairment in these rats and further survived, 
integrated and differentiated into GFAP and NF-200 positive neuronal cells after 16 weeks 
of transplantation [40].
Blurton-Jones et al. explored the role of neural stem cell transplantation in reversal of 
memory impairment. To study the effect of neural stem cells (NSCs) in AD pathology and 
cognitive functions, these cells were transplanted into aged triple transgenic mice that 
express mutant presenilin, tau and APP with aggressive Aβ load. Remarkably, transplanted 
NSCs were found to ameliorate loss in spatial learning and memory without altering Aβ and 
tau pathologies. Further, these cells increased synaptic density in diseased brain, which was 
assisted by BDNF. Loss of function studies have revealed that NSCs exert regenerative 
effects mediated by BDNF. It was further found that restoration of memory loss occurred 
when recombinant BDNF was additionally supplemented [15]. The same group recently 
reported that when these NSCs were genetically engineered to stably release the Aβ 
degrading enzyme neprilysin (NEP), they could augment synaptic plasticity as well as 
ameliorate underlying Aβ pathology in triple transgenic mice [41]. Neuralstem, Inc. had 
announced the first data on neural stem cells transplantation studies in an animal model of 
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AD. This group reported that HK532: IGF1 (NSI-532.IGF) cells ameliorate spatial learning 
deficits and improved memory in AD mice. To generate human insulin-like growth factor 1 
(IGF-1), a cortical neural stem cell line was engineered. IGF-1 cells also impart a wide-
range of neuroprotective properties [42]. Notably, the cells, which were administered in the 
peri-hippocampal region showed survival up to ten weeks. Also, mice with stem cell 
transplantation performed better than did control mice at fourteen weeks after the surgery. It 
would be reasonable to conclude that such preliminary studies point toward a potentially 
feasible therapeutic approach to treat AD in the future, and that the therapeutic effect of stem 
cells upon transplantation into the brain is supported by a combination of approaches and 
largely mediated or at least significantly influenced by paracrine effects.
IMMUNOMODULATORY EFFECTS OF STEM CELLS TARGETING AD 
PATHOLOGY
Reports also suggest that transplanted stem cells exerts some immunomodulatory response 
at the site of injury, leading to release of cytokines that further target the underlying AD 
pathology. Jin et al. highlighted the phenomenon of crosstalk between transplanted cells and 
endogenous neuroproliferative cells by the transplantation of neural precursor cells (NPCs) 
in focal cerebral ischemia of rat brain. In their earlier study they found reduced infarct 
volume and improved behavioral outcomes upon transplantation of NPCs in middle cerebral 
artery occlusion model of rat. In a more recent study neurogenesis was shown by an increase 
in BrdU labeling and expression of neuronal migration protein doublecortin in the ipsilateral 
SVZ whereas not in contralateral SVZ or subgranular zone (SGZ) in young and aged rats 
[43]. In another study, authors have administered umbilical cord blood-derived mesenchymal 
stem cells (UCB-MSCs) in double transgenic mice of PS1 and APP, which substantially 
ameliorated loss of spatial learning and memory by microglia activation. Further, levels of 
Aβ peptide, hyperphosphorylation of tau and BACE1 activity were reduced significantly. 
This neuroprotective effect by UCB-MSCs involved modulation of neuroinflammation due 
to reduction in pro-inflammatory and increase in anti-inflammatory cytokines, induced by 
microglia activation [44]. These findings suggest that UCB-MSC may act as a therapeutic 
agent to ameliorate decline in cognitive functions in AD model mice.
Besides amyloid plaque deposition and neurofibrillary tangle formation, vascular 
dysfunction also contributes to the AD pathophysiology. Vascular endothelial growth factor 
(VEGF) is also implicated in AD related neurodegeneration. Therefore Garcia et al used the 
strategy of providing VEGF by transplantation of overexpressing bone marrow derived 
mesenchymal cells into the lateral ventricles of brain using stereotaxic surgery in double 
transgenic mouse model with APPSWE/PS1dE9 mutations [45]. Behavioral and molecular 
parameters were assessed for vascularization and amyloid plaque deposition. Outcomes 
included reducing behavioral deficit and amyloid deposition besides inducing favored 
neovascularization. Yang et al. have used cell based approach and transplanted differentiated 
neuron like cells in APP/PS1 transgenic mice. They used human mesenchymal stem cells 
derived from Wharton’s jelly of umbilical cord and transdifferentiated into neuron-like cells 
(HUMSC-NCs) by tricyclodecan-9-yl-xanthogenate (D609). Transplantation of HUMSC-
NCs in a transgenic APP/PS1 mouse model significantly reduced Aβ load and improved 
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cognitive functions via increase in microglial activation and expression of the NEP and Aβ 
degrading enzymes insulin-degrading enzyme (IDE). Expression of pro-inflammatory 
markers associated with the modulation of M2-like microglia (a type of microglia classified 
based on its mannose receptor and its activation by IL-4 cytokine [46]) activation was 
reduced whereas expression of anti-inflammatory markers, such as interleukin-4 (IL4), was 
found to be increased [47]. Mesenchymal stem cells derived from bone marrow of male 
Sprague–Dawley rats were transplanted in female rats by tail vein injection [48]. BM-MSCs 
were found to increase expression of nestin andcholine acetyltransferase positive cells at the 
injured area in the brain. Notably, these cells displayed a reduction in amyloid plaques in 
hippocampus.
Thus, bone marrow cells bring about their therapeutic effect by mechanisms involving anti-
apoptotic activity, immunomodulation, and neurogenic properties. Furthermore, 
neurogenesis in the subgranular zone of dentate gyrus may act as an endogenous repair 
mechanism in AD via Wnt pathway in amyloid-related neurodegeneration associated with 
AD. Researchers also investigated the role of mesenchymal stem cells on hippocampal 
neurogenesis by co-culturing with the amyloid treated neural progenitor cells. Mesenchymal 
stem cells treatment to NPC significantly enhances the expression of GFAP, Ki67, HuD c, 
SOX2, and Nestin. Transplantation of these mesenchymal stem cells in Aβ-treated animals 
increased BrdU and HuD double positive cells in hippocampus at 2 and 4 weeks as 
compared to control and Aβ-treated alone animals [49]. This shows that MSC administration 
caused hippocampal neurogenesis and increased differentiation of NPC, which is modulated 
by Wnt pathway. If proven, this may provide a better therapeutic approach for treating AD 
patients than what is offered by anticholinesterase drugs. Zhang et al realized that neural 
stem cell transplantation could provide a better approach for the therapeutic treatment of AD 
and hypothesized that the transplantation of NSCs would ameliorate cognitive impairment 
by increased expression of synaptic proteins. Therefore, they isolated NSCs from mouse 
embryo at embryonic day 14 and transplanted these cells in both hippocampi of APP/PS1 
transgenic mice. Indeed, there was enhancement in cognitive functions analyzed by better 
spatial learning and memory after 8th weeks of transplantation as compared to the control 
group. Further, the expression of synaptophysin (SYN) and GAP-43 were found to be 
increased significantly. Hence, these results suggest that NPC induced cognitive 
improvement possibly by formation of new neural circuits [50].
Studies have also been carried out to mobilize the quiescent bone marrow stem cell 
population into the peripheral blood by using stimulating factors. Prakash et al evaluated the 
effect of granulocyte colony stimulating factor (GCSF) in Aβ induced memory loss in male 
adult Wistar rats, and they found significant escalation in behavioral performance after 
GCSF elevated the progenitor population and CD34 positive cells in the brain affecting 
neurogenesis [51]. Shetty et al. demonstrated the efficacy of mesenchymal stem cells 
(MSCs) derived from umbilical cord tissue in a Parkinson disease model [52]. They have 
studied the comparative therapeutic efficacy of MSCs from umbilical tissue and bone 
marrow as well as efficacy of undifferentiated versus differentiated cells in their model and 
found better efficacy of differentiated MSCs into dopaminergic phenotype when 
transplanted. As mesenchymal stem cells lack immunomodulatory activity, these cells 
provide a novel cellular approach to treat some neurological disorders. Several sources of 
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stem cells in combination with multiple approaches tested in pre-clinical AD models are 
further discussed in Table 1.
POTENTIAL ADVERSE EFFECTS OF STEM CELL THERAPY
Niche provides the regulatory molecules and suitable physicochemical environment to 
facilitate the cells to behave in a particular fashion [53]. These cells are exploited for 
therapeutic purposes, by isolating them from their niche which can pose some unexpected or 
undesirable outcomes such as tumorigenicity, which has a major concern. Very few studies 
have reported the potential adverse effect of these stem cells upon transplantation. In one of 
the studies, investigators evaluated the long term safety efficacy of 253G1-NSs (neural stem 
cells). The 253G1-NSs were transplanted to treat spinal cord injury (SCI) in SCID-NOD 
mice. These transplanted cells were found to have temporary improvement of motor function 
assessed by rota rod experiment for upto 47 days of post transplantation; however, this was 
followed by gradual deterioration in motor functioning [54]. It has also been shown to be 
involved in enhanced proliferation of grafted cells and tumor formation. The proportion of 
nestin positive cells have been found to be increased from 47 days and 103 post-
transplantation which suggests tumor formation in the long term by the grafted cells. In an 
18-years old patient with spinal cord injury at T10-T11, an olfactory mucosal cells were 
transplanted after three years. This led to severe back pain and paraplegia after 8 years. 
Further imaging revealed a mass formation of an intramedullary spinal cord [55].
The Yamanaka study of induced pluripotent stem cells opens up a possible window for 
untreatable diseases [56] as well as for stem cell clinical trials; even though the use of iPSCs 
also carries a risk for tumors formation. The generation of iPSCs involves retroviral 
transduction by the factors i.e. Oct3/4, Sox2, Klf4 and c-Myc [57]. The retroviral 
transduction of c-Myc is believed to increase a risk for tumorigenicity, hindering its clinical 
application. Further, the approach has also shown elimination of the c-Myc factor for iPSC 
generation, which is relatively safer than the earlier approach.
Therefore, an evaluation of safety efficacy of stem cells would provide us better therapeutic 
approach and its clinical application [58, 59].
THE PUTATIVE LINK OF BDNF AND CREB BEHIND STEM CELL MEDIATED 
REGENERATION
In brain BDNF and CREB (cAMP response element-binding protein) are believed to play a 
major role in complex memory formation, consolidation and retention [60–62]. It is also 
reported in both in-vivo and in-vitro studies that Aβ induced toxicity leads to 
downregulation of BDNF and its major regulatory molecule CREB. Hota et al studied the 
phosphorylation of CREB to investigate the molecular mechanism of bacoside action. 
Administration of Bacopa monniera leaf extractin hypobaric hypoxia induced rat model 
increased learning ability and ameliorated cognitive dysfunction [63]. Tota et al. investigated 
the effect of angiotensin II on spatial memory and BDNF expression in Sprague-Dawley 
male rats. Spatial memory was reduced as assessed by Morris water maze after angiotensin 
ICV administration, and no change was observed in BDNF expression [64]. In an in-vitro 
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study, Sharma et al. have investigated the role of CREB binding protein (CREB-BP) in 
neuronal differentiation. Their deletion construct p-CREB-BP were transfected into NT2 
cells and expression profile for neuronal genes i.e. SHH, Wnt, Notch and their mutant 
counterparts were evaluated. Defects in neuronal differentiation due to aberrant interaction 
of CREB-BP with their transcriptional regulatory proteins were investigated by CHIP-PCR 
and co-immunoprecipitation. Cells that are lacking in CREB, BROMO and HAT domains 
were found to show more proliferation and less differentiation whereas cells expressing 
CREB-BP showed less proliferation and more differentiation [65]. In 2009, Verma et al. 
suggested the role of dichlorvos in memory impairment by muscarinic receptor induced 
signal transduction and phosphorylation of CREB. Dichlorvos belongs to the 
organophosphate compounds which are widely used to as insecticide and may act as 
cholinesterase inhibitor [66]. Low doses of dichlorvos impaired the signal transduction 
linked to the adenylyl cyclase pathway and reduced CREB phosphorylation, leading to 
neurobehavioral impairment [67].
Neurotrophic factors such as BDNF, NGF and GDNF, which have been earlier shown to 
rescue hypoxia induced ischemic rat brain upon intravenous transplantation of UCB cells. 
This indicates an intrinsic role for neurotrophic factors, rather than direct differentiation, 
being significant in the stem cell mediated recovery [68]. It is pertinent to note that the role 
of BDNF has been well described in AD literature. BDNF levels are decreased when 
compared to healthy controls in the postmortem brains of AD patients [69–71]. Mature 
BDNF and its mRNA expression have also been shown to be confined to hippocampus and 
parietal cortex region of the brain [72–74]. BDNF is believed to exert neuroprotective effect 
in several neurodegenerative diseases. This may include pathologies characterized by Aβ-
induced neuronal cell death. Several studies have shown the complete reversal of 
neuroprotective effects driven by BDNF in neuronal culture death induced by Aβ in specific 
and dose-dependent manner [75–80]. BDNF induced neuroprotective effect has shown 
incorporation of the Trkβ receptor [76]. Moreover, specific Aβ42 induced neuronal cell 
death has been shown to be reversed by BDNF, in addition to other neurotrophins like IGF-1 
and GDNF [75].
Since CREB is a DNA binding protein and acts as a transcription factor for several genes, 
including c-fos, tyrosine hydroxylase, several neuronal peptides, and, importantly, 
neurotrophin BDNF, it is possible that an association exists between the role of BDNF 
expression and its regulation by CREB in rescuing learning and memory deficits [81, 82]. 
The function of CREB in the formation of spatial memory; conversion of this memory into 
long term memory and in neuronal plasticity is well documented [83]. It is well known that 
gene expression has a major role in memory consolidation as well as long term potentiation 
[83, 84]. These expression profiles are possibly activated through CREB and involvement of 
Ca++, protein kinase A (PKA) and by the activation of cAMP, but need additional studies 
[85–87]. The activated PKA would phosphorylate CREB protein which further regulates 
gene expression of several proteins [86, 88, 89]. Recently, Suzuki et al. have shown the 
effect of CREB on both short as well as long term memory. They have reported the increase 
in long term memory (LTM) as well as long term potential in hippocampus CA1 region in 
gain-of function CREB mice in which mice express dominant active CREB protein. In 
addition, they reported short term memory (STM) improvement in response to fear 
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conditioning and spatial clues, which was related with enhanced BDNF levels in these mice. 
Therefore, up-regulation of BDNF and CREB expression may mutually trigger enhancement 
of LTM and STM, suggesting that CREB mediated BDNF expression plays intrinsic role in 
memory consolidation and retrieval. (Fig. 2) [90].
CLINICAL STUDIES FOR TREATING NEURODE-GENERATIVE DISORDERS
Although a number of pre-clinical studies have been launched, very few clinical studies have 
been carried out so far. Venkataramana et al suggested the safety and effectiveness of 
autologous bone-marrow derived mesenchymal stem cells when transplanted unilaterally in 
PD patients. Notably, no adverse effects of these stem cells were seen, paving the way for 
additional studies in future [91]. In 2012, human retinal stem cells were used to treat PD 
patients. Authors isolated human retinal stem cells from retinal pigmented epithelium tissue 
from post-mortem eyes and cultured in-vitro to differentiate into dopaminergic neurons. 
These cells were then transplanted by stereotaxic operation into the post-commissural 
putamen of 12 PD patients. Interestingly, PET analysis showed a trend of increased 
dopamine release during the 6 month study [92]. In a current study of a phase I open-label 
clinical trial, authors evaluated the safety efficacy of intrathecal and intravenous 
transplantation of autologous bone marrow cells in children with cerebral palsy. Eighteen 
children with cerebral palsy, who had transplantation, were evaluated for motor and 
cognitive functions and MRI was done after the sixth month showing it was a safe procedure 
[93].
There are very few reports registered at www.clinicaltrials.gov of stem cells transplantation 
in AD patients, and their outcomes are largely unavailable. In 2011 Medipost Co Ltd. 
completed an open level, phase I safety and efficacy trial on Korean AD patients, but they 
did not post their outcome measures. Human umbilical cord blood derived MSCs were 
transplanted in AD patients at two different doses (3 million and 6 million) and endpoint 
analysis was measured by ADAS-cog scoring, PET imaging, and Aβ and tau levels in CSF 
[94]. Another group in China is currently recruiting AD patients in phase I/II trial in a 
similar study design with 30 probable AD participants, where patients are intravenously 
administered with 20 million human UCB-MSCs [95]. Medipost Co Ltd. has recently started 
a double blinded, placebo controlled, phase I/IIa trial in Korea where patients with mild to 
moderate AD will be subjected to repeated intraventricular administrations of UCB-MSCs 
and will be evaluated 24 weeks after first dose of transplantation [96].
CONCLUSION
Stem cells have promising translational significance as evident by emerging scientific data 
showing therapeutic benefits in several neurodegenerative disorders. The intrinsic pathways 
through which these cells exert their therapeutic effects still remain a challenge requiring 
thorough investigation. There are several studies describing the underlying pathways ranging 
from proliferation, differentiation, immunomodulation to cell replacement and paracrine 
effects at the site of neurodegeneration. Pre-clinical studies have shown variable effects 
depending on the types and sources of stem cells. Several studies explain this on the basis of 
paracrine effects either mediated by neurotrophic factors or endogenous cell proliferation. In 
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animal models of AD, stem cell transplantation has been shown to increase the expression of 
synaptic protein markers. Transplantation of mesenchymal stem cells has shown decrease in 
Aβ load due to microglial expression and escalation of Aβ degrading enzymes. A 
combinatorial approach, wherein stem cells are tagged with neurotransmitters or Aβ 
modifying enzymes may exhibit a substantial therapeutic outcome in AD. There is also 
insufficient literature to explain the actual relative contributions of exogenous cells and 
endogenous cells towards rescue of function after stem cell transplantation. There is absence 
of comparative studies involving different sources and types of stem cells i.e. 
undifferentiated versus differentiated cells in animal models of AD. Nevertheless, a few 
clinical studies have paved the way for clinical translation but such innovative treatments 
also carry substantial risk for tumor formation [55]. A thorough investigation is needed on 
the sources, types, stages, doses and routes of stem cell transplantation in AD model to 
validate their optimum therapeutic outcome. Moreover, the different stages of AD 
progression and other related pathologies may play a critical role in the outcome of the cell 
transplantation. Hence understanding the etiology of AD and its other pathologies is of 
paramount significance for successful clinical translation of stem cell related therapies [97].
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LIST OF ABBREVIATIONS
AD Alzheimer’s disease
APP Aβ precursor protein
Aβ Amyloid Beta
BACE1 β-Site Amyloid Precursor Protein-Cleaving Enzyme 1
BDNF Brain derived neurotrophic growth factor
BM-MSCs Bone-marrow derived mesenchymal stem cells
Brdu Bromodeoxyuridine
CHIP Chromatin Immunoprecipitation
CREB cAMP response element-binding protein
CREBBP CREB binding protein
DHA Docosahexaenoic acid
FAD Familial Alzheimer’s Disease
GCSF Granulocyte colony stimulating factor
GFAP Glial fibrillary acidic protein
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ICV Intracerebroventricular
IDE Insulin-degrading enzyme
IHC Immunohistochemistry iPSC-Induced pluripotent stem cells
LTM Long term memory
MRI Magnetic resonance imaging
NEP Neprilysin
NFT Neurofibrillary tangles
NPC Neural precursor cells
NPC Neural progenitor cells
NSC Neural stem cells
MWM Morris water maze
PD Parkinson Disease
PET Positron emission tomography
PPAR-γ peroxisome proliferator-activated receptor-γ
PS1 Presilin1
RMS Rostral migratory stream
SC Stem Cells
STM Short term memory
SVZ Subventricular zone
SYN Synaptophysin
TBI Traumatic Brain Injury
UCB-MSC Umbilical cord blood derived mesenchymal stem cells
VEGF Vascular endothelial growth factor
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Fig. 1. Outline for underlying mechanism in stem cell mediated reversal of AD pathology
Some underlying hypothesis may explain functional improvements in subjects of stem cell 
transplantation in AD. However, current experiments point to four possible explanations. A) 
Paracrine effects from release of neurotrophic factors by transplanted cells. B) 
Immunomodulatory effects by transplanted cells. C) Replacement of diseased cells by 
transplanted cells. D) Proliferation of endogenous cells. It is likely that all four processes 
operate in a coherent and synergistic manner to produce a final salutary effect(s).
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Fig. 2. Schematic showing the plausible mechanism behind stem cell mediated cognitive 
improvement in Alzheimer’s disease
We propose that the therapeutic effect of stem cells upon transplantation into the brain is 
largely mediated by the paracrine effects. The increase in neurotrophic factors, such as 
BDNF, results in increased CREB phosphorylation which in turn activates the genes that 
regulate cognitive functions and memory by involving one or other phenomena, such as 
neuroprotection, cell proliferation, differentiation, cell migration, synaptogenesis and 
neurogenesis.
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